ClinicaliQ Trial Snapshot
- Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients — Recruiting • Non-phase study • Oncology • NCT07673861.
- What is being tested: The clinical utility of circulating tumour DNA (ctDNA) analysis from blood samples to detect cancer resistance mechanisms and guide precision medicine treatment decisions, rather than relying solely on tissue biopsies.
- Patient eligibility overview: The trial includes cancer patients across various tumour types where ctDNA analysis can be performed on blood samples; specific eligibility criteria would depend on cancer stage, prior treatment history, and measurable ctDNA presence.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
ctDNA stands for circulating tumour DNA. As ctDNA is released by tumour cells into the blood stream, taking a blood sample and analysing it for ctDNA, can provide a lot of useful information about a patient's cancer. In certain situations, ctDNA can be used to screen for or detect cancer early, to aid clinical decisions about which treatment to give a patient, to provide information about if a cancer has become resistant to treatment, or provide information about how much cancer may be left after treatment (residual disease). The aim…
Eligibility Snapshot
- All cohorts: * Age ≥18 years old * Ability to provide written informed consent * Presence of metastatic or unresectable disease * Being reviewed and treated through medical oncology service at Royal Marsden Hospital Cohort 1: Locally Advanced/Metastatic NSCLC * Oncogene-addicted NSCLC (i.e. ESCAT Tier 1 oncogenic drivers: EGFR/ALK/ROS1/RET/MET/BRAF/NTRK/HER2/KRAS), AND * Progressive disease on targeted therapy (any line) within the 6 weeks prior to consent Cohort 2: Locally Advanced/Metastatic GIST * Locally advanced/metastatic gastrointestinal stromal tumour (GIST), AND * Progressive disease on targeted therapy (any line) within the 6 weeks prior to consent Cohort 3: Metastatic Colorectal Cancer • Metastatic colorectal cancer, left sided, RAS wild type, HER2 any status, AND * If HER2 negative or unknown: progressive disease on systemic anti-cancer therapy (SACT) with an anti-EGFR agent (e.g. cetuximab) within the 6 weeks prior to consent * If HER2 positive: progressive disease on first line systemic anti-cancer therapy (SACT) +/- an anti-EGFR agent within the 6 weeks prior to consent Cohort 4: Locally Advanced/Metastatic BTC * Identified targetable mutation (IDH1 mutation/HER2 amplification/FGFR2 fusion or rearrangement/NTRK fusion/BRAF V600E mutation/MMR deficiency [dMMR]), AND * Progressive disease on targeted therapy (any line) demonstrated within the 6 weeks prior to consent…
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.